BioCentury | Feb 14, 2020
Regulation

Controversy over stretching expanded access to off-label uses

Compassionate use is no exception to the axiom that sooner or later, someone will find an unexpected and controversial way to bend any law or regulation for unanticipated purposes. FDA’s expanded access, or compassionate use,...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Depleting platelets of inhibiting SOCS3 for atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Platelet depletion or inhibition of SOCS3, a platelet-induced regulator of macrophage polarization, could treat atherosclerosis. Blood levels of SOCS3 RNA were higher in 61 women presenting with myocardial infarction (MI)...
BC Innovations | Jul 18, 2019
Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting the pro-metastatic transcription factor BACH1 or its gene targets MCT1, HMOX1, HK2 and GADPH could treat metastatic lung cancer. In patients with metastasized lung cancer, levels of BACH1...
BC Extra | Jul 17, 2019
Preclinical News

July 17 Preclinical Quick Takes: Using CRISPR to edit TCRs, plus AAVs with synthetic promoters and AI for cancer diagnosis

CRISPR can modify TCRs to reprogram T cells  A Technical University Munich and Juno Therapeutics Inc. team led by TUM professor Dirk Busch used CRISPR to modify T cell receptors and create engineered T cells....
BioCentury | Apr 12, 2019
Politics, Policy & Law

Compassionate use of gene therapies raises ethical, commercial quandaries

No matter how quickly gene therapies are developed, there will always be a gap between the news that a product may radically alter the course of a disease and the drug’s approval. Like other investigational...
BC Innovations | Jan 29, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus In vitro , cell culture and mouse studies identified three TNC-based fusion proteins against S. aureus leukocidin ED or S. aureus γ-hemolysin AB that could help prevent and treat Staphylococcus infections. Screening of libraries...
BC Innovations | Jan 11, 2019
Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
BC Innovations | Dec 11, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
BioCentury | Dec 1, 2018
Politics, Policy & Law

China’s germline growing pain

How Chinese regulatory authorities respond over the long term to the CRISPR baby furor could influence its industry’s success on the global stage, as domestic and international stakeholders seek reassurance that the authorities are on...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies identified an oligomer macrocycle-based inhibitor of the β-catenin-TCF4 interaction that could help treat prostate cancer. Chemical synthesis of oligomer macrocycles designed to inhibit the interaction between TCF4 and β-catenin,...
Items per page:
1 - 10 of 148
BioCentury | Feb 14, 2020
Regulation

Controversy over stretching expanded access to off-label uses

Compassionate use is no exception to the axiom that sooner or later, someone will find an unexpected and controversial way to bend any law or regulation for unanticipated purposes. FDA’s expanded access, or compassionate use,...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Depleting platelets of inhibiting SOCS3 for atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Platelet depletion or inhibition of SOCS3, a platelet-induced regulator of macrophage polarization, could treat atherosclerosis. Blood levels of SOCS3 RNA were higher in 61 women presenting with myocardial infarction (MI)...
BC Innovations | Jul 18, 2019
Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting the pro-metastatic transcription factor BACH1 or its gene targets MCT1, HMOX1, HK2 and GADPH could treat metastatic lung cancer. In patients with metastasized lung cancer, levels of BACH1...
BC Extra | Jul 17, 2019
Preclinical News

July 17 Preclinical Quick Takes: Using CRISPR to edit TCRs, plus AAVs with synthetic promoters and AI for cancer diagnosis

CRISPR can modify TCRs to reprogram T cells  A Technical University Munich and Juno Therapeutics Inc. team led by TUM professor Dirk Busch used CRISPR to modify T cell receptors and create engineered T cells....
BioCentury | Apr 12, 2019
Politics, Policy & Law

Compassionate use of gene therapies raises ethical, commercial quandaries

No matter how quickly gene therapies are developed, there will always be a gap between the news that a product may radically alter the course of a disease and the drug’s approval. Like other investigational...
BC Innovations | Jan 29, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus In vitro , cell culture and mouse studies identified three TNC-based fusion proteins against S. aureus leukocidin ED or S. aureus γ-hemolysin AB that could help prevent and treat Staphylococcus infections. Screening of libraries...
BC Innovations | Jan 11, 2019
Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
BC Innovations | Dec 11, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
BioCentury | Dec 1, 2018
Politics, Policy & Law

China’s germline growing pain

How Chinese regulatory authorities respond over the long term to the CRISPR baby furor could influence its industry’s success on the global stage, as domestic and international stakeholders seek reassurance that the authorities are on...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies identified an oligomer macrocycle-based inhibitor of the β-catenin-TCF4 interaction that could help treat prostate cancer. Chemical synthesis of oligomer macrocycles designed to inhibit the interaction between TCF4 and β-catenin,...
Items per page:
1 - 10 of 148